GERN: Geron Corp Company Profile & Statistics

About

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Info & Links

CEO

JOHN A. SCARLETT

Headquarters

919 EAST HILLSDALE BOULEVARD, SUITE 250
FOSTER CITY, CA 94404, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

439

Employees

229

Geron Corp Statistics

Valuation Measures

Market Capitalization²

965.57M

Enterprise Value

998.69M

Enterprise Value/EBITDA(ttm)

-6.83

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

53.93

Price to Book(mrq)

5.42

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

97.94%

Operating Margin(ttm)

-682.48%

Profit Margin(ttm)

-1959.19%

Return on Equity(ttm)

-67.53%

Return on Invested Capital(ttm)

-39.80%

Return on Assets(ttm)

-45.46%

Income Statement

Revenue(ttm)

116.29M

Revenue Per Share(ttm)

0.18

Gross Profit(ttm)

113.83M

EBITDA(ttm)³

-146.23M

Net Income Available to Common(ttm)

-139.02M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

0.53

52-Week Change

-69.10%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

636.92M

Dividend Yield

0.00%

Float⁴

585.76M

% Held by Insiders

3.10%

% Held by Institutions

73.71%

Balance Sheet

Total Cash(mrq)

398.74M

Total Cash Per Share(mrq)

0.63

Total Debt(mrq)

118.73M

Total Debt/Equity(mrq)

44.26%

Current Ratio(mrq)

7.87%

Quick Ratio(mrq)

2.74%

Book Value Per Share(mrq)

0.42

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.07

Free Cash Flow(ytd)

-47.95M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

GERN

Geron Corp

Geron Corp Profile